Supplementary Online Content

Reibaldi M, Fallico M, Avitabile T, et al. Risk of Death Associated With Intravitreal Anti–Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-analysis. *JAMA Ophthalmol.* Published online November 21, 2019. doi:10.1001/jamaophthalmol.2019.4636

eTable 1. PRISMA Checklist

eTable 2. Search Strategy

eFigure 1. Risk of Bias Graph

eFigure 2. Risk of Bias Summary

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. PRISMA Checklist

Section/topic	#	Checklist item		
TITLE			1	
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1	
ABSTRACT				
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3-4	
INTRODUCTION	1		5-6	
Rationale	3	Describe the rationale for the review in the context of what is already known.	5	
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6	
METHODS			6-8	
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	-	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6-7	
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6	
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6	
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7	
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7	
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7	
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7	
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8	
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I²) for each meta-analysis.	8	

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

eTable 2. Search Strategy

Relevant text of randomized clinical trial
--

- 1. Randomized clinical trial
- 2. Randomized controlled trial
- 3. Randomized
- 4. Trial
- 5. Groups
- 6. Randomly
- 7. Drug therapy
- 8. Placebo
- 9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8

Relevant text of drugs

- 10. Anti
- 11. Vascular endothelial growth factor
- 12. VEGF
- 13. 10 and 11, or 10 and 12
- 14. Bevacizumab
- 15. Ranibizumab
- 16. Aflibercept
- 17. Pegaptanib
- 18. 13 or 14 or 15 or 16 or 17

Relevant test for retinal vein occlusion

- 19. Retinal vein occlusion
- 20. RVO
- 21. 19 or 20

Relevant text of diabetic macular oedema

- 22. Macular edema
- 23. Macular oedema
- 24. 22 or 23
- 25. Diabetic
- 26. Diabetes
- 27. 25 or 26
- 28. 24 and 27

Relevant text of age-related macular degeneration

- 29. Age related macular degeneration
- 30. exp macular degeneration/
- 31. exp choroidal neovascularization/
- 32. exp retinal degeneration/
- 33. exp. retinal neovascularization/
- 34. AMD or ARM or CNV
- 35. Maculopathy
- 36. 29 or 30 or 31 or 32 or 33 or 34 or 35


Combined (Final strategy)

- 37. 9 and 18 and 21
- 38. 9 and 18 and 28
- 39. 9 and 18 and 36

Footnote.Web sites and uniform resource locator: **PubMed**: http://www.ncbi.nlm.nih.gov/pubmed; **Cochrane**: http://www.cochranelibrary.com; **Medline**: http://www.ovid.com/site/catalog/databases/901.jsp;

Embase: http://www.embase.com

eFigure 1. Risk of Bias Graph



eFigure 2. Risk of Bias Summary

See and part See								
BAKER 2019 BERGER 2015 BOYER 2012 BROWN 2010 BROWN 2010 BROWN VISTA 2015 BROWN VID 2015 CALLANAN 2017 CAMPOCHIARO 2010 CLARK 2018 COMYN 2014 DO 2012 EPSTEIN 2012 GRAGOUDAS 2004 HATTENBACH 2017 HIGASHIYAMA 2013 ISHIBASHI 2015 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 NASSIN 2010 MITCHELL 2011 NGUYEN 2012 PIELEN 2015 RAMSZIN 2010 MITCHELL 2011 NGUYEN 2012 PIELEN 2015 RAMSZIN 2010 MITCHELL 2011 NGUYEN 2012 PIELEN 2015 RAMSZIN 2010 RASSIN 2010 MITCHELL 2011 NGUYEN 2020 RASSIN 2010 MITCHELL 2011 NGUYEN 2020 RASSIN 2010 MITCHELL 2011 NGUYEN 2020 RASSIN 2010 MITCHELL 2011 ROUYEN 2020 RASSIN 2010 MITCHELL 2011 ROUYEN 2020 RASSIN 2010 MITCHELL 2011 ROUYEN 2020 RASSIN 2010	ANTONOTAL 2002							
BERGER 2015 BOYER 2012 BROWN 2010 BROWN 2010 BROWN VISTA 2015 BROWN VISTA 2015 CALLANAN 2017 CAMPOCHIARO 2010 CLARK 2016 COMYN 2014 DO 2012 EPSTEIN 2012 GRAGOUDAS 2004 HATTENBACH 2017 HIGASHIYAMA 2013 ISHIBASHI 2015 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECH		_						
BOYER 2012 BROWN 2006 BROWN VISTA 2015 BROWN VISTA 2015 BROWN VIVID 2015 CALLANAN 2017 CAMPOCHIARO 2010 CLARK 2016 COMYN 2014 DO 2012 BPSTEIN 2012 GRAGOUDAS 2004 HATTENBACH 2017 HIGASHIYAMA 2013 ISHIBASHI 2015 KINGE 2010 KOH 2012 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECHBA		_		?				
BROWN 2016 BROWN VISTA 2015 BROWN VIVID 2015 CALLANAN 2017 CAMPOCHIARO 2010 CLARK 2016 COMYN 2014 DO 2012 EPSTEIN 2012 GRAGOUDAS 2004 HATTENBACH 2017 HIGASHIYAMA 2013 ISHIBASHI 2015 KINGE 2010 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 RASIN 2010 MASSIN 2010 MA		H	<u> </u>	•	_			_
BROWN 2010 BROWN VISTA 2015 BROWN VIVID 2015 CALLANAN 2017 CAMPOCHIARO 2010 CLARK 2016 COMYN 2014 DO 2012 EPSTEIN 2012 GRAGOUDAS 2004 HATTENBACH 2017 HIGASHIYAMA 2013 ISHIBASHI 2015 KINGE 2010 KOH 2012 KOROBELNIK 2014 KRIECHBAUM 2014 KRIE		H	<u> </u>		-		_	-
BROWN VISTA 2015 BROWN VIVID 2015 CALLANAN 2017 CAMPOCHIARO 2010 CLARK 2016 COMYN 2014 COMYN 2014 COMYN 2014 COMYN 2014 COMYN 2014 COMYN 2014 CRESTEIN 2012		<u> </u>	-	_	_		_	
BROWN VIVID 2015 CALLANAN 2017 CAMPOCHIARO 2010 CLARK 2016 COMYN 2014 COMYN 2		H		_	_		_	
CALLANAN 2017 CAMPOCHIARO 2010 CLARK 2016 COMYN 2014 DO 2012 GRAGOUDAS 2004 HATTENBACH 2017 HIGASHIYAMA 2013 ISHIBASHI 2015 KNOR 2010 KOROBELNIK 2014 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 MASSIN 2010 MASSIN 2		H	Ε.	-	-		-	
CAMPOCHIARO 2010 CLARK 2016 COMYN 2014 DO 2012 EPSTEIN 2012 GRAGOUDAS 2004 HATTENBACH 2017 HIGASHIYAMA 2013 ISHIBASHI 2015 KINGE 2010 KOH 2012 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 MASSIN 2010 MITCHELL 2011 NGUYEN 2009 NGUYEN 2012 PIELEN 2015 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADAYONI 2016 O		H	_		_		_	
COMYN 2014 DO 2012 EPSTEIN 2012 GRAGOUDAS 2004 HATTENBACH 2017 HIGASHIYAMA 2013 ISHIBASHI 2015 KINGE 2010 KOH 2012 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 MASSIN 2010 MITCHELL 2011 NGUYEN 2009 NGUYEN 2012 PIELEN 2015 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADAYONI 2016 O	CAMPOCHIARO 2010	•		•	_			
DO 2012 EPSTEIN 2012 GRAGOUDAS 2004 HATTENBACH 2017 HIGASHIYAMA 2013 ISHIBASHI 2015 KINGE 2010 KOH 2012 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 MASSIN 2010 MASSIN 2010 MITCHELL 2011 NGUYEN 2009 NGUYEN 2012 PIELEN 2015 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADDAYONI 2016 **O **O **O **O **O **O **O **O **O *	CLARK 2016	•	•	•	?	?	•	?
EPSTEIN 2012 GRAGOUDAS 2004 HATTENBACH 2017 HIGASHIYAMA 2013 ISHIBASHI 2015 KINGE 2010 KOH 2012 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 MASSIN 2010 MITCHELL 2011 NGUYEN 2009 NGUYEN 2009 RAMEZANI 2015 RAMEZANI 2015 RAMEZANI 2016 SACU 2009 SCOTT 2007 TADAYONI 2016 ?	COMYN 2014	•	•	•	?	•	?	•
GRAGOUDAS 2004 HATTENBACH 2017 HIGASHIYAMA 2013 ISHIBASHI 2015 KINGE 2010 KOH 2012 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2010 MASSIN 2010 MASSIN 2010 MITCHELL 2011 NGUYEN 2009 NGUYEN 2009 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADAYONI 2016 O	DO 2012	•	•	•	?	•	•	•
HATTENBACH 2017 HIGASHIYAMA 2013 ISHIBASHI 2015 KINGE 2010 KOH 2012 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 MASSIN 2010 MASSIN 2010 MITCHELL 2011 NGUYEN 2009 NGUYEN 2002 PIELEN 2015 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADAYONI 2016 **O **O **O **O **O **O **O **O **O **	EPSTEIN 2012	?	•	•	•	•	•	•
HIGASHIYAMA 2013 ISHIBASHI 2015 KINGE 2010 KOH 2012 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 MASSIN 2010 MITCHELL 2011 NGUYEN 2009 NGUYEN 2012 PIELEN 2015 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADAYONI 2016 RAME 2016 RINGE 2010 RING RAME 2016 REGILLO 2016	GRAGOUDAS 2004	•	•	•	•	•	•	?
ISHIBASHI 2015 KINGE 2010 KOH 2012 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 MASSIN 2010 MASSIN 2010 MITCHELL 2011 NGUYEN 2009 NGUYEN 2012 PIELEN 2015 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADAYONI 2016 P. O O O O O O O O O O O O O O O O O O O	HATTENBACH 2017	•	•	•	?	•	?	?
KINGE 2010	HIGASHIYAMA 2013	_	•	?	?	•	?	?
KOH 2012 KOROBELNIK 2014 KRIECHBAUM 2014 KRIECHBAUM 2014 KRIECHBAUM 2010 MASSIN 2010 MITCHELL 2011 NGUYEN 2009 NGUYEN 2012 PIELEN 2015 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADAYONI 2016 ? ? @ ? ? @ ? ? ? ? @ ? ? ? ? @ ? ? ? ? @ ? ? ? ? @ ? ? ? ? @ ? ? ? ? @ ? ? ? ? @ ? ? ? ? @ ? ? ? ? @ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? **TADAYONI 2016 *** **TADAYONI 2016 ***TADAYONI 2016		•	•	•	•	•	?	•
KOROBELNIK 2014 KRIECHBAUM 2014 Macugen Diabetic Retinopathy Study Group 2005 MASSIN 2010 MITCHELL 2011 NGUYEN 2009 NGUYEN 2012 PIELEN 2015 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADAYONI 2016 R		H	_	_	_		_	
KRIECHBAUM 2014 Macugen Diabetic Retinopathy Study Group 2005 MASSIN 2010 MITCHELL 2011 NGUYEN 2009 NGUYEN 2012 PIELEN 2015 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADAYONI 2016 ROWN RETINOPATHY STUDY RETINOP		_		_		_		
Macugen Diabetic Retinopathy Study Group 2005 MASSIN 2010 MITCHELL 2011 NGUYEN 2009 NGUYEN 2012 PIELEN 2015 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADAYONI 2016 MORE STUDEN STUDY MASSIN 2010 MORE STUDY MORE STUD		H		_	_	?	_	
MASSIN 2010 MITCHELL 2011 NGUYEN 2009 RGUYEN 2012 PIELEN 2015 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADAYONI 2016 ROWNITCHELL 2011 ROWN		<u> </u>				•		
MITCHELL 2011 NGUYEN 2009 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADAYONI 2016 M		<u> </u>	_	_	_	_	_	
NGUYEN 2009		H	_	_				
NGUYEN 2012 PIELEN 2015 RAMEZANI 2012 REGILLO 2008 SACU 2009 SCOTT 2007 TADAYONI 2016 ROUNT 2012 REGILLO 2018 REGILLO 2008 REGILLO 200			_	•	•		•	
RAMEZANI 2012 REGILLO 2008 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		H	_	•	•		•	
REGILLO 2008	PIELEN 2015	•	•	?	•	•	•	•
SACU 2009	RAMEZANI 2012	•	•	•	•	•	•	•
SCOTT 2007	REGILLO 2008	•	?	•	•	•	•	?
TADAYONI 2016	SACU 2009	•	•	•	•	•	•	•
	SCOTT 2007	•	•	•	?	•	?	?
WROBLEWSKI 2009 🕙 🕡 💿 🥙 🥙	TADAYONI 2016	•	•	?	•	?	•	?
	WROBLEWSKI 2009	•	•	•	•	?	•	•